Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GPR3 | P46089 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8710825 | 0.88 | ALDH1A1 (0.50) | KDM4EALDH1A1MAPTGLACYP1A2 | |
| SCHEMBL29386389 | 0.88 | ALDH1A1 (0.50) | KDM4EALDH1A1MAPTGLACYP1A2 | |
| SCHEMBL15346818 | 0.83 | KDM4E (0.46) | KDM4EGPR3EGFRALDH1A1CYP1A2 | |
| SCHEMBL30824482 | 0.83 | KDM4E (0.46) | KDM4EGPR3EGFRALDH1A1MAPT | |
| SCHEMBL382006 | 0.83 | KDM4E (0.46) | KDM4EGPR3EGFRALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL28102802 | 0.81 | KDM4E (0.44) | KDM4EGPR3EGFRALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL28174209 | 0.81 | KDM4E (0.44) | KDM4EGPR3EGFRALDH1A1CYP1A2 | |
| SCHEMBL28624806 | 0.79 | CYP1A2 (0.40) | KDM4EGPR3EGFRALDH1A1MAPT | |
| SCHEMBL3634933 | 0.79 | TLR8 (0.49) | KDM4EGPR3EGFRALDH1A1MAPT | |
| SCHEMBL30952029 | 0.79 | TLR8 (0.49) | KDM4EGPR3EGFRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119790050-A | Oxazole TRPML1 agonists and uses thereof | 利布拉医疗公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119546588-A | Pyridine checkpoint kinase 1 (CHK 1) inhibitors and uses thereof | 无界生物公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-118488945-A | Sulfonamide ribonucleotide reductase (RNR) inhibitors and uses thereof | 无界生物公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118434417-A | Cyclic sulfonamide ribonucleotide reductase (RNR) inhibitors and uses thereof | 无界生物公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-116507626-A | Compositions and methods for modulating short-chain dehydrogenase activity | 罗迪奥治疗公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-110036008-A | Compound, device and application thereof | 西吉隆医疗股份有限公司 | 2019-07-19 | — | — | CN | disclosed |
| CN-104710385-B | PDE10 inhibitor and compositions related and method | 奥默罗斯公司 | 2018-11-09 | — | — | CN | disclosed |
| US-7700552-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1910347-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007017144-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | KDM4E 4409/4885GPR3 405/4885EGFR 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.